Page 10 - Cancer

Cancer care should focus on patients rather than commerce: Lancet

Cancer care and innovation should be focused on outcomes that matter to patients rather than the commercial bottom line, say cancer experts in a Comment published in The Lancet Oncology journal. According to the Comment, industry's control of the research agenda has created a system that is predominantly focused on new cancer medicines at the expense of investigating new approaches to surgery, radiotherapy, palliative care, and prevention. The authors, consisting of global oncologists and patient advocates, also establish core guidelines for the development of a new patient-centred movement in cancer care - Common Sense Oncology. They claim that there has been a shift over the past few decades from predominantly publicly funded clinical trials designed to answer questions important to patients, to industry-funded trials which aim to achieve regulatory approval or commercial advantage. "While many cancer treatments make a real difference in the lives of our patients, there are growi

Aspartame under scanner: Is Diet Coke cancerous?

Aspartame, one of the most common artificial sweeteners in the world, is set to be declared a "possible carcinogen" by the World Health Organization's cancer research arm. Watch the video to know more

40% cancer cases caused by tobacco, alcohol; no clue in 20% cases: Expert

"The maximum number of patients of breast cancer and cervical cancer are found in women in urban areas. Cervical cancer patients are found more in rural areas than breast cancer patients"

New combination therapy cuts risk of breast cancer returning by 25%

The median duration of study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20 per cent and 57 per cent patients respectively

Tata Memorial Centre aims to double share in cancer treatment by 2030

Tata Memorial Centre (TMC) is aiming to double its share of cancer patients it serves per year to 20 per cent of the total number of such patients in the country by 2030 from the present 10 per cent, its director Rajendra Badwe said on Friday. Currently, the centre provides treatment to 10 per cent of the country's total cancer patients per year. The premier cancer treatment and research institute, backed by Tata Group and the government, is expanding facilities and educational capabilities to train the manpower, which will be required to achieve the target, Badwe told reporters here. "Presently, India has about 13 lakh cancer patients every year, 10 per cent of those are treated at Tata Hospital. We would like that to be doubled to somewhere about 20 per cent of the total national problem," the director said, adding that the aim to double is being sought to be achieved by the end of the decade. He said the hospital feels there will be a huge increase in the total number of patient

AstraZeneca announces launch of cancer medication Tremelimumab in UAE

AstraZeneca has announced the launch of its revolutionary cancer medication, IMJUDO (tremelimumab) in the UAE

Pfizer pouring windfall profits from Covid-19 vaccine into cancer battle

The U.S. government will end the COVID Public Health Emergency on Thursday that allowed millions of Americans to receive vaccines, tests and treatments at no cost

Covid-19 dropped to fourth leading cause of death in US last year

U.S. deaths fell last year, and COVID-19 dropped to the nation's No. 4 cause, the Centers for Disease Control and Prevention reported Thursday. COVID-19 deaths trailed those caused by heart disease, cancer and injuries such as drug overdoses, motor vehicle fatalities and shootings. In 2020 and 2021, only heart disease and cancer were ahead of the coronavirus. U.S. deaths usually rise year-to-year, in part because the nation's population has been growing. The pandemic accelerated that trend, making 2021 the deadliest in U.S. history, with more than 3.4 million deaths. But 2022 saw the first drop in deaths since 2009. The 2022 tally was about 3.3 million a 5 per cent decline from 2021 but still much higher than in the years before the pandemic. The CDC cautioned that last year's numbers are preliminary and may change a little after further analysis. Coronavirus-associated death rates fell for nearly all Americans. The virus was deemed the underlying cause of about 187,000 U.S. death

Unleashing the potential of immunology to improve public health

.

J&J, cancer victims ordered to start settlement talks in bankruptcy

A federal judge ordered a new round of settlement talks between Johnson & Johnson and lawyers who spurned the company's offer to pay $8.9 billion to end tens of thousands of cancer claims

J&J accused by US of misusing bankruptcy to end talc cancer suits

J&J has an $8.9 billion settlement agreement with the "vast majority" of the law firms representing talc claimants, said the company's head of litigation

J&J accused by US of misusing bankruptcy to end talc cancer suits

The healthcare products maker is trying for the second time to get itself out of a jam as cheaply as possible, using the Chapter 11 filing of LTL Management

Easily spread virus exploits genomic weaknesses, causes cancer: Study

Researchers have described in a study how the Epstein-Barr virus (EBV), the ubiquitous virus easily spread through bodily fluids, not only exploits genomic weaknesses to cause cancer, but also reduces the body's ability to suppress it. The researchers at the University of California (UC) San Diego, US, said that more than 90 per cent of the world's population has been infected by the EBV, usually during childhood, and that while most of the infections it causes are mild and pass, the virus persists in the body, becoming latent or inactive, sometimes reactivating. The EBV spreads easily through bodily fluids, primarily saliva, through activities such kissing, sharing drinks or using the same eating utensils. The researchers' findings showed "how a virus can induce cleavage of human chromosome 11, initiating a cascade of genomic instability that can potentially activate a leukemia-causing oncogene and inactivate a major tumour suppressor," said senior study author Don Cleveland, ...

Indian startup PredOmix develops AI-based blood test to detect 32 cancers

The company's OncoVeryx-F is a patented technology that combines metabolomics (study of small molecules) and AI to identify metabolite signatures of multiple cancers in a single test

BioNTech signs deal to co-develop OncoC4's cancer antibody drug

A late-stage trial for the drug has been planned for this year, the companies said

Pfizer to acquire Seagen for $43 bn to deepen reach into treating cancer

Pfizer will spend USD 43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay USD 229 per Seagen share. Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen's antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer's capabilities and expertise," Pfizer Chairman and CEO Dr. Albert Bourla said in a statement. Bothell, Washington-based Seagen Inc. is a biotech drug developer. Its key products use monoclonal antibodies that bind to the surface of a tumour cell to deliver a cancer-killing agent while sparing surrounding healthy tissue. Monoclonal antibodies are lab-made proteins delivered mostly by IV at an infusion center, according to the Cleveland Clinic. Seagen's top seller, Adcetris, treats lymph system cancers. It brought in USD 839 million in sales last year, a 19 per cent increase over

No link between use of ranitidine and cancer risk: Nature study

Ranitidine has been in existence for over four decades and has been on the WHO list of essential medicines for several years

For insurance cover against cancer, maintain high sum for hospitalisation

February 4 is World Cancer Day: here is advice on how meet ancillary expenses in treating disease

World Cancer Day: WHO calls for action for prevention, early detection

On World Cancer Day, World Health Organization (WHO) has called for intensified action across the Southeast Asian region to strengthen health systems to prevent and detect cancers early.

Tata Capital Healthcare Fund infuses $ 10 mn in Mumbai Oncocare Centre

MOC, a unit of Cellcure Cancer Center Pvt Ltd, plans to utilise the newly infused capital to expand across India in next 18 months, the company said in a statement